PCM
SGMO

Peregrine Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Peregrine Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-607,868
Closed -$6.98M – 328
2018
Q4 		$6.98M Sell
607,868
-3,625
-0.6% -$45K 0.2% 199
2018
Q3 		$10.4M Buy
611,493
+4,430
+0.7% +$67.3K 0.25% 152
2018
Q2 		$8.62M Buy
607,063
+206,657
+52% +$3.43M 0.22% 150
2018
Q1 		$7.61M Buy
+400,406
New +$8.56M 0.19% 193

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Peregrine Capital Management's SGMO Position: Q1 2019 in Review

Peregrine Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2019, closing a stake of 607,868 shares — an estimated $6.98M sold.

Peregrine Capital Management first reported a position in SGMO in Q1 2018 and held it in 4 quarters. The position peaked at $10.4M in Q3 2018. 187 funds tracked by Wall St. Rank hold SGMO as of Q1 2019.

  • Peregrine Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2019 after selling out during the quarter.
  • Peregrine Capital Management sold 607,868 SANGAMO THERAPEUTICS INC shares in Q1 2019, an estimated $6.98M.
  • Peregrine Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 4 quarters.
  • Peregrine Capital Management's SANGAMO THERAPEUTICS INC position peaked at $10.4M in Q3 2018.
  • 187 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2019.

Based on Peregrine Capital Management's 13F filing for Q1 2019, filed 12 Apr 2019.